IRLAB Therapeutics AB (publ) - Asset Resilience Ratio

Latest as of September 2025: 64.58%

IRLAB Therapeutics AB (publ) (IRLAB-A) has an Asset Resilience Ratio of 64.58% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of IRLAB Therapeutics AB (publ) for a breakdown of total debt and financial obligations.

Liquid Assets

Skr110.13 Million

≈ $11.85 Million USD Cash + Short-term Investments

Total Assets

Skr170.55 Million

≈ $18.35 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how IRLAB Therapeutics AB (publ)'s Asset Resilience Ratio has changed over time. See IRLAB Therapeutics AB (publ) (IRLAB-A) net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down IRLAB Therapeutics AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see IRLAB Therapeutics AB (publ) stock valuation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Skr110.13 Million	64.58%
Short-term Investments	Skr0.00	0%
Total Liquid Assets	Skr110.13 Million	64.58%

Asset Resilience Insights

Very High Liquidity: IRLAB Therapeutics AB (publ) maintains exceptional liquid asset reserves at 64.58% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

IRLAB Therapeutics AB (publ) Industry Peers by Asset Resilience Ratio

Compare IRLAB Therapeutics AB (publ)'s asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Argen-X F:1AE	Biotechnology	25.67%
Tubize-Fin BR:TUB	Biotechnology	0.05%
BrightGene Bio Medical Technology C SHG:688166	Biotechnology	1.00%
Dashenlin Pharm Grp Co Ltd SHG:603233	Biotechnology	0.02%
Staidson Beijing Biopharma SHE:300204	Biotechnology	7.93%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	41.25%
Ardelyx Inc NASDAQ:ARDX	Biotechnology	41.14%
Xiangxue Pharmaceutical SHE:300147	Biotechnology	0.05%

Annual Asset Resilience Ratio for IRLAB Therapeutics AB (publ) (2016–2024)

The table below shows the annual Asset Resilience Ratio data for IRLAB Therapeutics AB (publ).

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	49.13%	Skr66.92 Million ≈ $7.20 Million	Skr136.21 Million ≈ $14.66 Million	-13.72pp
2023-12-31	62.84%	Skr111.31 Million ≈ $11.98 Million	Skr177.12 Million ≈ $19.06 Million	-15.28pp
2022-12-31	78.12%	Skr252.78 Million ≈ $27.20 Million	Skr323.56 Million ≈ $34.82 Million	-6.94pp
2021-12-31	85.07%	Skr401.90 Million ≈ $43.25 Million	Skr472.45 Million ≈ $50.84 Million	+10.21pp
2020-12-31	74.85%	Skr277.01 Million ≈ $29.81 Million	Skr370.07 Million ≈ $39.83 Million	+21.73pp
2019-12-31	53.12%	Skr110.53 Million ≈ $11.89 Million	Skr208.07 Million ≈ $22.39 Million	-6.65pp
2018-12-31	59.77%	Skr134.44 Million ≈ $14.47 Million	Skr224.94 Million ≈ $24.21 Million	+13.93pp
2017-12-31	45.84%	Skr74.71 Million ≈ $8.04 Million	Skr162.97 Million ≈ $17.54 Million	+23.09pp
2016-12-31	22.75%	Skr25.74 Million ≈ $2.77 Million	Skr113.11 Million ≈ $12.17 Million	--

pp = percentage points

About IRLAB Therapeutics AB (publ)

ST:IRLAB-A Sweden Biotechnology

Market Cap

$12.86 Million

Skr119.48 Million SEK

Market Cap Rank

#26241 Global

#563 in Sweden

Share Price

Skr1.41

Change (1 day)

-0.85%

52-Week Range

Skr1.41 - Skr7.58

All Time High

Skr104.95